A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-02-20

AUTHORS

Begoña Pineda, Angel Diaz-Lagares, José Alejandro Pérez-Fidalgo, Octavio Burgués, Inés González-Barrallo, Ana B. Crujeiras, Juan Sandoval, Manel Esteller, Ana Lluch, Pilar Eroles

ABSTRACT

BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. METHODS: Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K array) from Illumina. The epigenetic silencing of those methylated genes in the discovery cohort were validated by bisulfite pyrosequencing (PyroMark Q96 System version 2.0.6, Qiagen) and qRT-PCR in an independent cohort of TN patients and in TN cell lines. RESULTS: Twenty-four and 30 patients were included in the discovery and validation cohorts, respectively. In the discovery cohort, nine genes were differentially methylated: six presented higher methylation in non-responder patients (LOC641519, LEF1, HOXA5, EVC2, TLX3, CDKL2) and three greater methylation in responder patients (FERD3L, CHL1, and TRIP10). After validation, a two-gene (FER3L and TRIP10) epigenetic score predicted RCB = 0 with an area under the ROC curve (AUC) = 0.905 (95% CI = 0.805-1.000). Patients with a positive epigenetic two-gene score showed 78.6% RCB = 0 versus only 10.7% RCB = 0 if signature were negative. CONCLUSIONS: These results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted. More... »

PAGES

33

References to SciGraph publications

  • 2011-11-07. Twist contributes to hormone resistance in breast cancer by down-regulating estrogen receptor alpha in ONCOGENE
  • 2015-05-05. Identification and validation of a two-gene expression index for subtype classification and prognosis in Diffuse Large B-Cell Lymphoma in SCIENTIFIC REPORTS
  • 2015-02-02. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value in NATURE COMMUNICATIONS
  • 2002-01. Gene expression profiling predicts clinical outcome of breast cancer in NATURE
  • 2004-02. p21-activated kinase signaling in breast cancer in BREAST CANCER RESEARCH
  • 2018-10-15. Actin–microtubule crosstalk in cell biology in NATURE REVIEWS MOLECULAR CELL BIOLOGY
  • 2014-08-07. Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) in ANNALS OF SURGICAL ONCOLOGY
  • 2011-02-07. Functional characterization of Trip10 in cancer cell growth and survival in JOURNAL OF BIOMEDICAL SCIENCE
  • 2018-11-23. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer in CLINICAL EPIGENETICS
  • 2017-05-02. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients in BMC CANCER
  • 2012-08-14. TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production in BMC BIOLOGY
  • 2016-09-27. DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients in SCIENTIFIC REPORTS
  • 2015-02-19. A urine-based methylation signature for risk stratification within low-risk prostate cancer in BRITISH JOURNAL OF CANCER
  • 2013-10-08. Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer in INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
  • 2017-08-25. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial in NPJ BREAST CANCER
  • 2017-11-07. CLDN6 promotes chemoresistance through GSTP1 in human breast cancer in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • Journal

    TITLE

    Clinical Epigenetics

    ISSUE

    1

    VOLUME

    11

    Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s13148-019-0626-0

    DOI

    http://dx.doi.org/10.1186/s13148-019-0626-0

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1112259630

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30786922


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/06", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Biological Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0604", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Genetics", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cell Line, Tumor", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "DNA Methylation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Epigenesis, Genetic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Female", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Profiling", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gene Expression Regulation, Neoplastic", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "High-Throughput Nucleotide Sequencing", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Microtubule-Associated Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Middle Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Minor Histocompatibility Antigens", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Myogenic Regulatory Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Neoadjuvant Therapy", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nuclear Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Repressor Proteins", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sequence Analysis, DNA", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Taxoids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Triple Negative Breast Neoplasms", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
              "id": "http://www.grid.ac/institutes/grid.413448.e", 
              "name": [
                "Biomedical Research Institute (INCLIVA), Valencia, Spain", 
                "Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain", 
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Pineda", 
            "givenName": "Bego\u00f1a", 
            "id": "sg:person.0700213352.89", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700213352.89"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Present Address: Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, Santiago de Compostela, Spain", 
              "id": "http://www.grid.ac/institutes/grid.488911.d", 
              "name": [
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain", 
                "Present Address: Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, Santiago de Compostela, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Diaz-Lagares", 
            "givenName": "Angel", 
            "id": "sg:person.01330373705.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330373705.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
              "id": "http://www.grid.ac/institutes/grid.411308.f", 
              "name": [
                "Biomedical Research Institute (INCLIVA), Valencia, Spain", 
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "P\u00e9rez-Fidalgo", 
            "givenName": "Jos\u00e9 Alejandro", 
            "id": "sg:person.01037166257.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037166257.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pathology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
              "id": "http://www.grid.ac/institutes/grid.411308.f", 
              "name": [
                "Biomedical Research Institute (INCLIVA), Valencia, Spain", 
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "Pathology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Burgu\u00e9s", 
            "givenName": "Octavio", 
            "id": "sg:person.0776667566.61", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776667566.61"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
              "id": "http://www.grid.ac/institutes/grid.411308.f", 
              "name": [
                "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gonz\u00e1lez-Barrallo", 
            "givenName": "In\u00e9s", 
            "id": "sg:person.011167742170.04", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011167742170.04"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Present Address: Laboratory of Epigenomics in Endocrinology and Nutrition, Instituto de Investigacion Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela University (USC) and CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Madrid, Spain", 
              "id": "http://www.grid.ac/institutes/grid.413448.e", 
              "name": [
                "Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain", 
                "Present Address: Laboratory of Epigenomics in Endocrinology and Nutrition, Instituto de Investigacion Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela University (USC) and CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Madrid, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Crujeiras", 
            "givenName": "Ana B.", 
            "id": "sg:person.01116346206.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116346206.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Biomarkers and Precision Medicne Unit (UByMP), Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLaFeValencia), Valencia, Spain", 
              "id": "http://www.grid.ac/institutes/grid.476458.c", 
              "name": [
                "Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain", 
                "Biomarkers and Precision Medicne Unit (UByMP), Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLaFeValencia), Valencia, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sandoval", 
            "givenName": "Juan", 
            "id": "sg:person.01142034603.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142034603.86"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats (ICREA), Badalona, Barcelona, Catalonia Spain", 
              "id": "http://www.grid.ac/institutes/grid.425902.8", 
              "name": [
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain", 
                "Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain", 
                "Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats (ICREA), Barcelona, Catalonia Spain", 
                "Instituci\u00f3 Catalana de Recerca i Estudis Avan\u00e7ats (ICREA), Badalona, Barcelona, Catalonia Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Esteller", 
            "givenName": "Manel", 
            "id": "sg:person.01322160364.94", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322160364.94"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain", 
              "id": "http://www.grid.ac/institutes/grid.411308.f", 
              "name": [
                "Biomedical Research Institute (INCLIVA), Valencia, Spain", 
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "Oncology Department, Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lluch", 
            "givenName": "Ana", 
            "id": "sg:person.01274311013.83", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274311013.83"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "COST action, CA15204 Brussels, Belgium", 
              "id": "http://www.grid.ac/institutes/grid.450763.3", 
              "name": [
                "Biomedical Research Institute (INCLIVA), Valencia, Spain", 
                "Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain", 
                "COST action, CA15204 Brussels, Belgium"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Eroles", 
            "givenName": "Pilar", 
            "id": "sg:person.0644567534.68", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644567534.68"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/1741-7007-10-73", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039222519", 
              "https://doi.org/10.1186/1741-7007-10-73"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2015.7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049589060", 
              "https://doi.org/10.1038/bjc.2015.7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41580-018-0067-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1107633714", 
              "https://doi.org/10.1038/s41580-018-0067-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10147-013-0614-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031915035", 
              "https://doi.org/10.1007/s10147-013-0614-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1245/s10434-014-3908-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026850864", 
              "https://doi.org/10.1245/s10434-014-3908-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12885-017-3297-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1084956325", 
              "https://doi.org/10.1186/s12885-017-3297-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13148-018-0575-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1110157104", 
              "https://doi.org/10.1186/s13148-018-0575-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms6899", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1014368826", 
              "https://doi.org/10.1038/ncomms6899"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41523-017-0025-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091341578", 
              "https://doi.org/10.1038/s41523-017-0025-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/srep10006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1049254201", 
              "https://doi.org/10.1038/srep10006"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13046-017-0627-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1092578286", 
              "https://doi.org/10.1186/s13046-017-0627-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/srep33435", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042635967", 
              "https://doi.org/10.1038/srep33435"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/bcr961", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048974392", 
              "https://doi.org/10.1186/bcr961"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1423-0127-18-12", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036036565", 
              "https://doi.org/10.1186/1423-0127-18-12"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2011.483", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1044059226", 
              "https://doi.org/10.1038/onc.2011.483"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/415530a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043001094", 
              "https://doi.org/10.1038/415530a"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-02-20", 
        "datePublishedReg": "2019-02-20", 
        "description": "BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature.\nMETHODS: Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB\u2009=\u20090) or non-responder (non-pCR or RCB\u2009>\u20090) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K array) from Illumina. The epigenetic silencing of those methylated genes in the discovery cohort were validated by bisulfite pyrosequencing (PyroMark Q96 System version 2.0.6, Qiagen) and qRT-PCR in an independent cohort of TN patients and in TN cell lines.\nRESULTS: Twenty-four and 30 patients were included in the discovery and validation cohorts, respectively. In the discovery cohort, nine genes were differentially methylated: six presented higher methylation in non-responder patients (LOC641519, LEF1, HOXA5, EVC2, TLX3, CDKL2) and three greater methylation in responder patients (FERD3L, CHL1, and TRIP10). After validation, a two-gene (FER3L and TRIP10) epigenetic score predicted RCB\u2009=\u20090 with an area under the ROC curve (AUC)\u2009=\u20090.905 (95% CI\u2009=\u20090.805-1.000). Patients with a positive epigenetic two-gene score showed 78.6% RCB\u2009=\u20090 versus only 10.7% RCB\u2009=\u20090 if signature were negative.\nCONCLUSIONS: These results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s13148-019-0626-0", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1042271", 
            "issn": [
              "1868-7075", 
              "1868-7083"
            ], 
            "name": "Clinical Epigenetics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "11"
          }
        ], 
        "keywords": [
          "epigenetic signatures", 
          "Infinium HumanMethylation450 BeadChip", 
          "TN cell lines", 
          "epigenetic silencing", 
          "triple-negative breast cancer", 
          "HumanMethylation450 BeadChip", 
          "epigenetic assessment", 
          "bisulfite pyrosequencing", 
          "genes", 
          "discovery cohort", 
          "qRT-PCR", 
          "higher methylation", 
          "epigenetic score", 
          "cell lines", 
          "methylation", 
          "pathological complete response", 
          "greater methylation", 
          "further insight", 
          "non-responder patients", 
          "neoadjuvant chemotherapy", 
          "Illumina", 
          "silencing", 
          "BeadChip", 
          "pyrosequencing", 
          "FERD3L", 
          "DNA", 
          "signatures", 
          "independent cohort", 
          "triple-negative breast cancer patients", 
          "prediction of pCR", 
          "breast cancer patients", 
          "response", 
          "discovery", 
          "prediction of response", 
          "RCB", 
          "responder patients", 
          "complete response", 
          "TN patients", 
          "TNBC patients", 
          "validation cohort", 
          "cancer patients", 
          "prospective validation", 
          "breast cancer", 
          "patients", 
          "insights", 
          "role", 
          "cohort", 
          "lines", 
          "ROC curve", 
          "chemotherapy", 
          "previous response", 
          "cancer", 
          "scores", 
          "biopsy", 
          "responders", 
          "prediction", 
          "findings", 
          "validation", 
          "study", 
          "area", 
          "results", 
          "assessment", 
          "samples", 
          "curves", 
          "epigenetic methylation-based signature", 
          "methylation-based signature", 
          "methyloma study", 
          "two-gene (FER3L and TRIP10) epigenetic score", 
          "two-gene score", 
          "TRIP10 genes", 
          "two-gene epigenetic signature"
        ], 
        "name": "A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients", 
        "pagination": "33", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1112259630"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s13148-019-0626-0"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30786922"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s13148-019-0626-0", 
          "https://app.dimensions.ai/details/publication/pub.1112259630"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2021-12-01T19:45", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_829.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s13148-019-0626-0"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13148-019-0626-0'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13148-019-0626-0'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13148-019-0626-0'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13148-019-0626-0'


     

    This table displays all metadata directly associated to this object as RDF triples.

    385 TRIPLES      22 PREDICATES      136 URIs      110 LITERALS      28 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s13148-019-0626-0 schema:about N0e90fcc4ac4148aeaa8dca9232e76b39
    2 N0f322e61d8f6449b9ac4a730c8646c60
    3 N164ab883f05f4bf290f0d910978845d7
    4 N180f9a2b8a2a41b6b6e945e5bdee8d20
    5 N40782a4fd4f44363a2513c99dfa4c066
    6 N4be9b5cacd3e48d68c00b0d91b6f6481
    7 N50b3df6cecec4fceaeb4078f4ef38fa1
    8 N54560dba0d764520a099eae76e557ed5
    9 N553f90cd147a49c9b6cd38f096ce80e9
    10 N5e7bc7c8e7714b4eaf3a4c9c49eb7814
    11 N956f3e1f8d8d49d294791f4f8f44a7c7
    12 N95d4fb865fa04edab9985cc8bc8dc9c4
    13 N98d0d53b276e4f6db3017c9f5bd0b266
    14 N9a540c6c51f54f7c9361fca9c9042ff6
    15 Na1509868b2964f2b98be5e5636715179
    16 Na1fef5e4b68143caa77efcec73c6ee51
    17 Na7091f38771a4589a2d7e8e86873fd1d
    18 Nbc3f8cf291054bd783d40bc6ed9d214c
    19 Nd26dbcbead434aa19dc5b6b7a4c284bd
    20 Nd6559b57f48341da8fd8958b238d5832
    21 Neac65755453d40468f7f5503c5f441fc
    22 anzsrc-for:06
    23 anzsrc-for:0604
    24 anzsrc-for:11
    25 anzsrc-for:1112
    26 schema:author N1d9f4c389793471184ea476ec7ab5069
    27 schema:citation sg:pub.10.1007/s10147-013-0614-x
    28 sg:pub.10.1038/415530a
    29 sg:pub.10.1038/bjc.2015.7
    30 sg:pub.10.1038/ncomms6899
    31 sg:pub.10.1038/onc.2011.483
    32 sg:pub.10.1038/s41523-017-0025-7
    33 sg:pub.10.1038/s41580-018-0067-1
    34 sg:pub.10.1038/srep10006
    35 sg:pub.10.1038/srep33435
    36 sg:pub.10.1186/1423-0127-18-12
    37 sg:pub.10.1186/1741-7007-10-73
    38 sg:pub.10.1186/bcr961
    39 sg:pub.10.1186/s12885-017-3297-2
    40 sg:pub.10.1186/s13046-017-0627-9
    41 sg:pub.10.1186/s13148-018-0575-z
    42 sg:pub.10.1245/s10434-014-3908-y
    43 schema:datePublished 2019-02-20
    44 schema:datePublishedReg 2019-02-20
    45 schema:description BACKGROUND: Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) varies between 30 and 40% approximately. To provide further insight into the prediction of pCR, we evaluated the role of an epigenetic methylation-based signature. METHODS: Epigenetic assessment of DNA extracted from biopsy archived samples previous to NAC from TNBC patients was performed. Patients included were categorized according to previous response to NAC in responder (pCR or residual cancer burden, RCB = 0) or non-responder (non-pCR or RCB > 0) patients. A methyloma study was performed in a discovery cohort by the Infinium HumanMethylation450 BeadChip (450K array) from Illumina. The epigenetic silencing of those methylated genes in the discovery cohort were validated by bisulfite pyrosequencing (PyroMark Q96 System version 2.0.6, Qiagen) and qRT-PCR in an independent cohort of TN patients and in TN cell lines. RESULTS: Twenty-four and 30 patients were included in the discovery and validation cohorts, respectively. In the discovery cohort, nine genes were differentially methylated: six presented higher methylation in non-responder patients (LOC641519, LEF1, HOXA5, EVC2, TLX3, CDKL2) and three greater methylation in responder patients (FERD3L, CHL1, and TRIP10). After validation, a two-gene (FER3L and TRIP10) epigenetic score predicted RCB = 0 with an area under the ROC curve (AUC) = 0.905 (95% CI = 0.805-1.000). Patients with a positive epigenetic two-gene score showed 78.6% RCB = 0 versus only 10.7% RCB = 0 if signature were negative. CONCLUSIONS: These results suggest that pCR in TNBC could be accurately predicted with an epigenetic signature of FERD3L and TRIP10 genes. Further prospective validation of these findings is warranted.
    46 schema:genre article
    47 schema:inLanguage en
    48 schema:isAccessibleForFree true
    49 schema:isPartOf N51642e35edae4a7a8cefa2948aae1eb0
    50 N5af71a95f15641f4b13d0e582f8f4fc2
    51 sg:journal.1042271
    52 schema:keywords BeadChip
    53 DNA
    54 FERD3L
    55 HumanMethylation450 BeadChip
    56 Illumina
    57 Infinium HumanMethylation450 BeadChip
    58 RCB
    59 ROC curve
    60 TN cell lines
    61 TN patients
    62 TNBC patients
    63 TRIP10 genes
    64 area
    65 assessment
    66 biopsy
    67 bisulfite pyrosequencing
    68 breast cancer
    69 breast cancer patients
    70 cancer
    71 cancer patients
    72 cell lines
    73 chemotherapy
    74 cohort
    75 complete response
    76 curves
    77 discovery
    78 discovery cohort
    79 epigenetic assessment
    80 epigenetic methylation-based signature
    81 epigenetic score
    82 epigenetic signatures
    83 epigenetic silencing
    84 findings
    85 further insight
    86 genes
    87 greater methylation
    88 higher methylation
    89 independent cohort
    90 insights
    91 lines
    92 methylation
    93 methylation-based signature
    94 methyloma study
    95 neoadjuvant chemotherapy
    96 non-responder patients
    97 pathological complete response
    98 patients
    99 prediction
    100 prediction of pCR
    101 prediction of response
    102 previous response
    103 prospective validation
    104 pyrosequencing
    105 qRT-PCR
    106 responder patients
    107 responders
    108 response
    109 results
    110 role
    111 samples
    112 scores
    113 signatures
    114 silencing
    115 study
    116 triple-negative breast cancer
    117 triple-negative breast cancer patients
    118 two-gene (FER3L and TRIP10) epigenetic score
    119 two-gene epigenetic signature
    120 two-gene score
    121 validation
    122 validation cohort
    123 schema:name A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
    124 schema:pagination 33
    125 schema:productId N693ef9d4925a4924b1c3b8a7bfe089bd
    126 Nc1d9435001304326bd52bf33fcf6c6a8
    127 Neb6393fa0d384f98a96f33047122828a
    128 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112259630
    129 https://doi.org/10.1186/s13148-019-0626-0
    130 schema:sdDatePublished 2021-12-01T19:45
    131 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    132 schema:sdPublisher N3dc95e3f27244034941502f0744096c6
    133 schema:url https://doi.org/10.1186/s13148-019-0626-0
    134 sgo:license sg:explorer/license/
    135 sgo:sdDataset articles
    136 rdf:type schema:ScholarlyArticle
    137 N0e90fcc4ac4148aeaa8dca9232e76b39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    138 schema:name Minor Histocompatibility Antigens
    139 rdf:type schema:DefinedTerm
    140 N0f322e61d8f6449b9ac4a730c8646c60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    141 schema:name Middle Aged
    142 rdf:type schema:DefinedTerm
    143 N164ab883f05f4bf290f0d910978845d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    144 schema:name Triple Negative Breast Neoplasms
    145 rdf:type schema:DefinedTerm
    146 N180f9a2b8a2a41b6b6e945e5bdee8d20 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Cell Line, Tumor
    148 rdf:type schema:DefinedTerm
    149 N1d9f4c389793471184ea476ec7ab5069 rdf:first sg:person.0700213352.89
    150 rdf:rest N2e329e54ffdc4ba5b7871efa01196c5c
    151 N233a42caafc84a4d94a9c0a1047905e7 rdf:first sg:person.011167742170.04
    152 rdf:rest Nca99562eb664498da949c83900debe49
    153 N2e329e54ffdc4ba5b7871efa01196c5c rdf:first sg:person.01330373705.24
    154 rdf:rest N4bf1f877215440b8a0d780d16d520283
    155 N3dc95e3f27244034941502f0744096c6 schema:name Springer Nature - SN SciGraph project
    156 rdf:type schema:Organization
    157 N40782a4fd4f44363a2513c99dfa4c066 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Adult
    159 rdf:type schema:DefinedTerm
    160 N4be9b5cacd3e48d68c00b0d91b6f6481 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Female
    162 rdf:type schema:DefinedTerm
    163 N4bf1f877215440b8a0d780d16d520283 rdf:first sg:person.01037166257.56
    164 rdf:rest Nb9ac0d4bac6249ef9d75c2e723c632cb
    165 N50b3df6cecec4fceaeb4078f4ef38fa1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Gene Expression Regulation, Neoplastic
    167 rdf:type schema:DefinedTerm
    168 N51642e35edae4a7a8cefa2948aae1eb0 schema:volumeNumber 11
    169 rdf:type schema:PublicationVolume
    170 N54560dba0d764520a099eae76e557ed5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Nuclear Proteins
    172 rdf:type schema:DefinedTerm
    173 N553f90cd147a49c9b6cd38f096ce80e9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Neoadjuvant Therapy
    175 rdf:type schema:DefinedTerm
    176 N5af71a95f15641f4b13d0e582f8f4fc2 schema:issueNumber 1
    177 rdf:type schema:PublicationIssue
    178 N5e7bc7c8e7714b4eaf3a4c9c49eb7814 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Aged
    180 rdf:type schema:DefinedTerm
    181 N693ef9d4925a4924b1c3b8a7bfe089bd schema:name pubmed_id
    182 schema:value 30786922
    183 rdf:type schema:PropertyValue
    184 N956f3e1f8d8d49d294791f4f8f44a7c7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Taxoids
    186 rdf:type schema:DefinedTerm
    187 N95d4fb865fa04edab9985cc8bc8dc9c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Gene Expression Profiling
    189 rdf:type schema:DefinedTerm
    190 N98d0d53b276e4f6db3017c9f5bd0b266 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Microtubule-Associated Proteins
    192 rdf:type schema:DefinedTerm
    193 N9a540c6c51f54f7c9361fca9c9042ff6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Humans
    195 rdf:type schema:DefinedTerm
    196 N9df4566dafd743ffadda46cc35fb5338 rdf:first sg:person.0644567534.68
    197 rdf:rest rdf:nil
    198 Na1509868b2964f2b98be5e5636715179 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    199 schema:name Treatment Outcome
    200 rdf:type schema:DefinedTerm
    201 Na1fef5e4b68143caa77efcec73c6ee51 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    202 schema:name High-Throughput Nucleotide Sequencing
    203 rdf:type schema:DefinedTerm
    204 Na7091f38771a4589a2d7e8e86873fd1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    205 schema:name Repressor Proteins
    206 rdf:type schema:DefinedTerm
    207 Na8bf12d112d94bd99d9c40dd26cfca5b rdf:first sg:person.01274311013.83
    208 rdf:rest N9df4566dafd743ffadda46cc35fb5338
    209 Nb0f382ded7514fe4a66b7b3a59fe32ca rdf:first sg:person.01142034603.86
    210 rdf:rest Nccfefb064f1a43ed8fa8d3b86d7732f3
    211 Nb9ac0d4bac6249ef9d75c2e723c632cb rdf:first sg:person.0776667566.61
    212 rdf:rest N233a42caafc84a4d94a9c0a1047905e7
    213 Nbc3f8cf291054bd783d40bc6ed9d214c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    214 schema:name Sequence Analysis, DNA
    215 rdf:type schema:DefinedTerm
    216 Nc1d9435001304326bd52bf33fcf6c6a8 schema:name dimensions_id
    217 schema:value pub.1112259630
    218 rdf:type schema:PropertyValue
    219 Nca99562eb664498da949c83900debe49 rdf:first sg:person.01116346206.49
    220 rdf:rest Nb0f382ded7514fe4a66b7b3a59fe32ca
    221 Nccfefb064f1a43ed8fa8d3b86d7732f3 rdf:first sg:person.01322160364.94
    222 rdf:rest Na8bf12d112d94bd99d9c40dd26cfca5b
    223 Nd26dbcbead434aa19dc5b6b7a4c284bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    224 schema:name Myogenic Regulatory Factors
    225 rdf:type schema:DefinedTerm
    226 Nd6559b57f48341da8fd8958b238d5832 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    227 schema:name Epigenesis, Genetic
    228 rdf:type schema:DefinedTerm
    229 Neac65755453d40468f7f5503c5f441fc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    230 schema:name DNA Methylation
    231 rdf:type schema:DefinedTerm
    232 Neb6393fa0d384f98a96f33047122828a schema:name doi
    233 schema:value 10.1186/s13148-019-0626-0
    234 rdf:type schema:PropertyValue
    235 anzsrc-for:06 schema:inDefinedTermSet anzsrc-for:
    236 schema:name Biological Sciences
    237 rdf:type schema:DefinedTerm
    238 anzsrc-for:0604 schema:inDefinedTermSet anzsrc-for:
    239 schema:name Genetics
    240 rdf:type schema:DefinedTerm
    241 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    242 schema:name Medical and Health Sciences
    243 rdf:type schema:DefinedTerm
    244 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    245 schema:name Oncology and Carcinogenesis
    246 rdf:type schema:DefinedTerm
    247 sg:journal.1042271 schema:issn 1868-7075
    248 1868-7083
    249 schema:name Clinical Epigenetics
    250 schema:publisher Springer Nature
    251 rdf:type schema:Periodical
    252 sg:person.01037166257.56 schema:affiliation grid-institutes:grid.411308.f
    253 schema:familyName Pérez-Fidalgo
    254 schema:givenName José Alejandro
    255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037166257.56
    256 rdf:type schema:Person
    257 sg:person.01116346206.49 schema:affiliation grid-institutes:grid.413448.e
    258 schema:familyName Crujeiras
    259 schema:givenName Ana B.
    260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116346206.49
    261 rdf:type schema:Person
    262 sg:person.011167742170.04 schema:affiliation grid-institutes:grid.411308.f
    263 schema:familyName González-Barrallo
    264 schema:givenName Inés
    265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011167742170.04
    266 rdf:type schema:Person
    267 sg:person.01142034603.86 schema:affiliation grid-institutes:grid.476458.c
    268 schema:familyName Sandoval
    269 schema:givenName Juan
    270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01142034603.86
    271 rdf:type schema:Person
    272 sg:person.01274311013.83 schema:affiliation grid-institutes:grid.411308.f
    273 schema:familyName Lluch
    274 schema:givenName Ana
    275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274311013.83
    276 rdf:type schema:Person
    277 sg:person.01322160364.94 schema:affiliation grid-institutes:grid.425902.8
    278 schema:familyName Esteller
    279 schema:givenName Manel
    280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322160364.94
    281 rdf:type schema:Person
    282 sg:person.01330373705.24 schema:affiliation grid-institutes:grid.488911.d
    283 schema:familyName Diaz-Lagares
    284 schema:givenName Angel
    285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01330373705.24
    286 rdf:type schema:Person
    287 sg:person.0644567534.68 schema:affiliation grid-institutes:grid.450763.3
    288 schema:familyName Eroles
    289 schema:givenName Pilar
    290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644567534.68
    291 rdf:type schema:Person
    292 sg:person.0700213352.89 schema:affiliation grid-institutes:grid.413448.e
    293 schema:familyName Pineda
    294 schema:givenName Begoña
    295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700213352.89
    296 rdf:type schema:Person
    297 sg:person.0776667566.61 schema:affiliation grid-institutes:grid.411308.f
    298 schema:familyName Burgués
    299 schema:givenName Octavio
    300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0776667566.61
    301 rdf:type schema:Person
    302 sg:pub.10.1007/s10147-013-0614-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031915035
    303 https://doi.org/10.1007/s10147-013-0614-x
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1038/415530a schema:sameAs https://app.dimensions.ai/details/publication/pub.1043001094
    306 https://doi.org/10.1038/415530a
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1038/bjc.2015.7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049589060
    309 https://doi.org/10.1038/bjc.2015.7
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1038/ncomms6899 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014368826
    312 https://doi.org/10.1038/ncomms6899
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1038/onc.2011.483 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044059226
    315 https://doi.org/10.1038/onc.2011.483
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.1038/s41523-017-0025-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091341578
    318 https://doi.org/10.1038/s41523-017-0025-7
    319 rdf:type schema:CreativeWork
    320 sg:pub.10.1038/s41580-018-0067-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107633714
    321 https://doi.org/10.1038/s41580-018-0067-1
    322 rdf:type schema:CreativeWork
    323 sg:pub.10.1038/srep10006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049254201
    324 https://doi.org/10.1038/srep10006
    325 rdf:type schema:CreativeWork
    326 sg:pub.10.1038/srep33435 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042635967
    327 https://doi.org/10.1038/srep33435
    328 rdf:type schema:CreativeWork
    329 sg:pub.10.1186/1423-0127-18-12 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036036565
    330 https://doi.org/10.1186/1423-0127-18-12
    331 rdf:type schema:CreativeWork
    332 sg:pub.10.1186/1741-7007-10-73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039222519
    333 https://doi.org/10.1186/1741-7007-10-73
    334 rdf:type schema:CreativeWork
    335 sg:pub.10.1186/bcr961 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048974392
    336 https://doi.org/10.1186/bcr961
    337 rdf:type schema:CreativeWork
    338 sg:pub.10.1186/s12885-017-3297-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084956325
    339 https://doi.org/10.1186/s12885-017-3297-2
    340 rdf:type schema:CreativeWork
    341 sg:pub.10.1186/s13046-017-0627-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092578286
    342 https://doi.org/10.1186/s13046-017-0627-9
    343 rdf:type schema:CreativeWork
    344 sg:pub.10.1186/s13148-018-0575-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1110157104
    345 https://doi.org/10.1186/s13148-018-0575-z
    346 rdf:type schema:CreativeWork
    347 sg:pub.10.1245/s10434-014-3908-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1026850864
    348 https://doi.org/10.1245/s10434-014-3908-y
    349 rdf:type schema:CreativeWork
    350 grid-institutes:grid.411308.f schema:alternateName Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
    351 Pathology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
    352 schema:name Biomedical Research Institute (INCLIVA), Valencia, Spain
    353 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    354 Oncology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
    355 Pathology Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
    356 rdf:type schema:Organization
    357 grid-institutes:grid.413448.e schema:alternateName Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    358 Present Address: Laboratory of Epigenomics in Endocrinology and Nutrition, Instituto de Investigacion Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela University (USC) and CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Madrid, Spain
    359 schema:name Biomedical Research Institute (INCLIVA), Valencia, Spain
    360 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
    361 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    362 Department of Physiology, Faculty of Medicine, University of Valencia, Valencia, Spain
    363 Present Address: Laboratory of Epigenomics in Endocrinology and Nutrition, Instituto de Investigacion Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela University (USC) and CIBER Fisiopatologia de la Obesidad y Nutricion (CIBERobn), Madrid, Spain
    364 rdf:type schema:Organization
    365 grid-institutes:grid.425902.8 schema:alternateName Institució Catalana de Recerca i Estudis Avançats (ICREA), Badalona, Barcelona, Catalonia Spain
    366 schema:name Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
    367 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    368 Institució Catalana de Recerca i Estudis Avançats (ICREA), Badalona, Barcelona, Catalonia Spain
    369 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia Spain
    370 Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain
    371 rdf:type schema:Organization
    372 grid-institutes:grid.450763.3 schema:alternateName COST action, CA15204 Brussels, Belgium
    373 schema:name Biomedical Research Institute (INCLIVA), Valencia, Spain
    374 COST action, CA15204 Brussels, Belgium
    375 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    376 rdf:type schema:Organization
    377 grid-institutes:grid.476458.c schema:alternateName Biomarkers and Precision Medicne Unit (UByMP), Instituto de Investigación Sanitaria La Fe (IISLaFeValencia), Valencia, Spain
    378 schema:name Biomarkers and Precision Medicne Unit (UByMP), Instituto de Investigación Sanitaria La Fe (IISLaFeValencia), Valencia, Spain
    379 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
    380 rdf:type schema:Organization
    381 grid-institutes:grid.488911.d schema:alternateName Present Address: Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, Santiago de Compostela, Spain
    382 schema:name Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain
    383 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain
    384 Present Address: Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), CIBERONC, Santiago de Compostela, Spain
    385 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...